China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corpora...(ts.Our increased marketing efforts and d...),Health
ts. Our increased marketing efforts and distribution expansion will boost future growth in the rest of 2009. We continue to expect China's healthcare reform to bring real and significant change to the Chinese pharmaceutical industry. China Pharma is well-positioned to quickly adjust its marketing and product strategy according to the new regulatory environment when it becomes certain, and to drive shareholder value."
Conference Call
The Company will hold a conference call at 8:00 am ET on May 15, 2009 to discuss fiscal first quarter 2009 results. Listeners may access the call by dialing 1-800-901-5241or 1-617-786-2963 for international callers, access code: 38020856. A webcast will also be available through CPHI's website at http://www.chinapharmaholdings.com . A replay of the call will be available through May 22, 2009. Listeners may access the replay by dialing 1-888-286- 8010 or 1-617-801-6888 for international callers, access code: 72616938.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company with
rapidly growing profit that develops, manufactures, and markets treatments for
a wide range of high incidence and high mortality conditions in China,
including cardiovascular, CNS, infectious, and digestive diseases. The
Company's cost-effective, high margin business model is driven by market
demand and supported by a scalable GMP-certified manufacturing infrastructure.
In addition, the Company has a broad and expanding distribution network across
30 provinces, municipalities and autonomous regions. The Company is registered
in Delaware, USA. Helpson Medical & Biotechnology Co., Ltd. (Helpson), located
in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China
Pharma Holdings, Inc. For more information about China Pharma Holdings, Inc.,
please visit '/>"/>
| SOURCE China Pharma Holdings, Inc. Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. Chinas 1-child policy could backfire on its elderly
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
5. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
6. China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China
7. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
8. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
9. Supplier Assessments to Help Buyers Identify Reliable China Exporters
10. Study shows lead-based paint problem isnt isolated to China
11. Bracco Announces Initiative to Save Children in China at 2007 Annual Meeting of CGI
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |